Will the FDA Eliminate Self-Affirmed GRAS? What the Proposed Rule Could Mean

The conversation around self-affirmed GRAS is evolving quickly, with lawmakers and regulators signaling potential changes that could reshape how food ingredients are evaluated and brought to market. While the FDA has not eliminated the pathway, proposed reforms and increased scrutiny suggest that companies relying on this framework should begin preparing now. For businesses, the real question is not just what the rule says—but how to respond strategically and remain compliant in a shifting regulatory environment.

How Self-Affirmed GRAS Works Today

The legal foundation for GRAS determinations without FDA preapproval

Under current law, companies can determine that a substance is “Generally Recognized as Safe” without formal FDA preapproval, provided the conclusion is supported by publicly available scientific evidence and expert consensus. This framework is rooted in the Federal Food, Drug, and Cosmetic Act and has long allowed businesses flexibility to pursue FDA approval of food ingredients through alternative pathways.

However, this flexibility is also what critics refer to as the GRAS loophole FDA, as companies are not required to notify the agency of their determinations before marketing a product. This means companies must independently ensure their safety conclusions are legally and scientifically sound.

Key considerations under the current GRAS framework include:

• Companies are responsible for compiling and maintaining all supporting safety data
• Expert panel reviews must be credible, unbiased, and well-documented
• There is no mandatory premarket review unless voluntarily submitted
• Regulatory risk remains with the company, even without FDA involvement

As regulatory priorities continue to evolve, federal agencies are placing greater emphasis on transparency, oversight, and accountability within the food safety system. This signals that companies relying on self-affirmed pathways should be prepared for increased scrutiny and potential changes in how determinations are evaluated.

The role of scientific panels and expert consensus in GRAS determinations

A valid GRAS determination depends on a rigorous scientific process. Companies typically rely on independent expert panels to evaluate safety data, published research, and exposure levels.

This process often includes:

• Comprehensive literature reviews of toxicology and safety studies
• Evaluation of intended use levels and dietary exposure
• Consensus opinions from qualified experts in relevant scientific fields

While this process can be robust, the FDA does not standardize it as it does for formal submissions, contributing to ongoing concerns about consistency and transparency across the industry.

Why companies sometimes choose not to submit GRAS notifications to the FDA

Although a voluntary GRAS notification requirement exists, companies may choose not to submit for several strategic and operational reasons. In many cases, businesses prioritize flexibility and speed, especially in competitive markets where timing can directly impact revenue and market share.

Common reasons companies rely on self-affirmed GRAS instead of notifying the FDA include:

• Speed to market: Avoiding FDA review can accelerate product launches
• Confidentiality: Proprietary formulations and supporting data remain private
• Cost considerations: Formal submissions require significant time, legal review, and scientific resources
• Regulatory control: Companies maintain direct oversight of their own safety determinations

However, choosing not to notify the FDA does not eliminate regulatory risk. It can actually increase exposure if the determination is later questioned during inspections, enforcement actions, or litigation, especially if documentation is incomplete or not aligned with current expectations.

As legislative attention around the GRAS pathway continues to grow, companies should carefully evaluate whether avoiding notification today could create compliance challenges in the future

The FDA’s Proposed Shift Toward Mandatory Notification

Key elements of the proposed GRAS regulatory changes

Recent discussions around GRAS regulatory reform suggest that the FDA may move toward requiring companies to notify the agency of all GRAS determinations. This would represent a major shift, reducing reliance on internal conclusions and increasing direct regulatory involvement in ingredient evaluations.

These potential changes reflect a broader push for transparency and consistency across the food industry, particularly in how safety determinations are documented and reviewed.

According to industry analysis and policy updates, proposed changes may include:

• Mandatory submission of GRAS determinations before commercialization
• Increased transparency around safety data and expert evaluations
• Expanded FDA authority to review and challenge determinations
• More standardized expectations for scientific support and documentation

If implemented, these changes could significantly impact how companies approach product development, compliance planning, and risk management. Businesses may need to adopt more structured regulatory strategies earlier in the process to avoid delays or enforcement issues.

How the proposed rule could increase FDA oversight of food ingredients

If implemented, these changes would bring GRAS determinations closer to traditional fda food ingredient approval processes. This means more direct FDA involvement, increased documentation requirements, and potentially longer timelines before products can enter the market.

In practice, this could lead to:

• Greater scrutiny of scientific evidence and methodologies
• More frequent requests for additional data or clarification
• Increased enforcement actions for non-compliant ingredients

While this may improve overall safety transparency, it also raises operational and legal challenges for companies that have historically relied on the flexibility of the current system.

Expected timelines for rulemaking, public comments, and implementation

Regulatory changes of this scale do not happen overnight. Updates to the GRAS framework must go through a structured federal rulemaking process, which allows for industry input and agency review before any final requirements take effect.

Typically, this process includes:

• Publication of a proposed rule outlining the intended changes
• A public comment period where stakeholders can provide feedback
• Review and revision by the agency based on submitted comments
• Final rule issuance followed by phased implementation timelines

While momentum around reform is increasing, companies should understand that changes may unfold gradually. However, early awareness and preparation are critical, as once finalized, compliance expectations can shift quickly.

Recent developments from federal agencies and HHS indicate that updates to the GRAS pathway are actively being evaluated, though final timelines and requirements remain uncertain.

Legal and Compliance Implications for the Food Industry

Recordkeeping and historical safety data challenges

One of the most immediate concerns for companies is whether existing GRAS determinations will withstand future scrutiny. Many businesses may need to revisit older safety assessments to ensure they meet evolving standards.

Common challenges include:

• Incomplete or outdated scientific documentation
• Lack of standardized expert panel procedures
• Difficulty reconstructing historical safety justifications

These issues can create significant exposure if regulators request documentation that no longer meets current expectations.

Impact on ingredient suppliers and food product manufacturers

The ripple effects of potential GRAS ingredient compliance changes extend across the supply chain. Ingredient suppliers, manufacturers, and brand owners may all face new obligations.

For example:

• Suppliers may need to provide more detailed safety data to customers
• Manufacturers may need to verify the compliance status of every ingredient used
• Contracts and liability allocation between parties may require revision

This is not just a regulatory issue, it is a business risk management issue that affects product development, sourcing, and market strategy.

How FDA Atty assists companies with GRAS determinations and regulatory strategy

This is where the distinction matters: the FDA sets the rules, but companies need practical legal guidance to apply them.

At FDA Atty, Marc Sanchez works directly with businesses to:

• Evaluate and strengthen existing GRAS determinations
• Develop defensible regulatory strategies before FDA scrutiny arises
• Respond to enforcement actions, warning letters, or compliance concerns
• Align product development with evolving FDA expectations

Rather than repeating what the FDA publishes, FDA Atty focuses on helping companies make informed decisions, reduce risk, and move forward with confidence.

If your company relies on self-affirmed GRAS or is preparing for potential regulatory changes, having a clear legal strategy is essential, not optional.